	Application No.	Applicant(s)	
		BLOOD ET AL.	
Notice of Allowability	10/040,547 Examiner	Art Unit	
	Chih-Min Kam	1653	
The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in to or other appropriate communing the Community of	nis application. If not included ication will be mailed in due co	ourse, THIS
1. This communication is responsive to 3/1/04.			
2. The allowed claim(s) is/are 8-19 and 28-33.			
3. \boxtimes The drawings filed on <u>04 January 2002</u> are accepted by th	e Examiner.		
 4. ☐ Acknowledgment is made of a claim for foreign priority unall All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have 2. ☐ Certified copies of the priority documents have 3. ☐ Copies of the certified copies of the priority do International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submined including changes required by the Notice of Draftspers 1) ☐ hereto or 2) ☐ to Paper No./Mail Date (b) ☐ including changes required by the attached Examiner Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1) ☐ hereto as th	e been received. e been received in Application cuments have been received in Application of this communication to file a MENT of this application. Initted. Note the attached EXAMER reason(s) why the oath or cost be submitted. Son's Patent Drawing Review of Samendment / Comment or in 1.84(c)) should be written on the the header according to 37 CFR posit of BIOLOGICAL MATE	No In this national stage application this national stage application is reply complying with the requirement. MINER'S AMENDMENT or NO declaration is deficient. (PTO-948) attached In the Office action of edrawings in the front (not the late). RIAL must be submitted. No	uirements OTICE OF
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 3. Information Disclosure Statements (PTO-1449 or PTO/SB/Paper No./Mail Date Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ⊠ Interview Sur Paper No./N 08), 7. ⊠ Examiner's A	fail Date <u>0504</u> . .mendment/Comment statement of Reasons for Allov	vance SSA OW AMINER

Application/Control Number: 10/040,547

Art Unit: 1653

An **Examiner's Amendment** to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Stephen Slusher on May 20, 2004.

Examiner's Amendments to the Claims:

Cancel claim 34.

Claims 8, 10, 12, 17, 28 and 29 have been amended as follows:

- 8. (Currently amended) A pharmaceutical composition [for stimulating sexual response in a mammal], comprising a peptide [and] in a pharmaceutically acceptable aqueous carrier, wherein said peptide is a free acid or a pharmaceutically acceptable salt thereof comprising the sequence Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH.
- 10. (Currently amended) The pharmaceutical composition of claim 8, wherein said peptide has an [amino terminus] acetylated amino group at amino terminus.
- 12. (Currently amended) A method for stimulating sexual response in a mammal, comprising administering a pharmaceutically sufficient amount of a composition comprising a peptide or pharmaceutically acceptable salt thereof of the formula Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH for a time and under conditions effective to stimulate a sexual response.
- 17. (Currently amended) The method of claim 12, wherein administering comprises [administering by] a method of administration selected from the group consisting of administration by injection, administration through mucous membranes, buccal administration, oral administration, dermal administration, inhalation administration and nasal administration.
- 28. (Currently amended) A <u>purified</u> peptide or pharmaceutically acceptable salt thereof consisting of [substantially pure] Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH.
- 29. (Currently amended) [A] <u>An isolated</u> peptide or pharmaceutically acceptable salt thereof consisting of [isolated peptide of the sequence] Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue

Application/Control Number: 10/040,547

Art Unit: 1653

fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (571) 272-0951. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9306 for regular communications and (703) 308-4227 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Chih-Min Kam, Ph. D. CYK Patent Examiner

May 20, 2004

CHAST PLEASE N CHRISTOPHER S. F. LOW SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1800